



Contacts: Bret L. Udem
Media Relations
Tel. (425) 493-2293
Fax. (425) 493-2010

FOR RELEASE
September 5, 2006

COMBIMATRIX MOLECULAR DIAGNOSTICS ANNOUNCES COMMERCIAL LAUNCH OF ITS FIRST GENETIC TEST FROM ITS CLIA CERTIFIED LABORATORY

Newport Beach, Calif. – (BUSINESS WIRE) – September 5, 2006 – Acacia Research Corporation (Nasdaq: CBMX:ACTG) announced today that its CombiMatrix group’s subsidiary, CombiMatrix Molecular Diagnostics (CMDX) has commercially launched its first molecular diagnostic service. Physicians are now able to prescribe this test for their patients.

This first offering utilizes CMDX’ Constitutional Genetic Array Test (CGAT), which can genetically identify over 50 common genetic disorders in one test. This array is already being sold in Europe, and is now being offered as a service in the US, after internal clinical validation. CMDX will be featuring this test through a number of sales and marketing efforts during the upcoming Annual Meeting of the American Society of Human Genetics, in New Orleans on October 9-13, 2006.

Over two thirds of young children with developmental disorders are either undiagnosed or mis-diagnosed through conventional techniques, making it difficult to provide appropriate treatment or counseling. CMDX’ CGAT array is designed to provide a cost and time effective approach to accurately identify the specific genomic abnormality that is the cause of the clinical disorder.

“With this launch, our CLIA laboratory is open for business. This is a major technical and scientific milestone for CMDX,” stated Matt Watson, CEO of CMDX. “During the next quarter we anticipate launching our Melanoma (skin cancer) product, and several other products are in various stages of development. We will provide more detailed information on our next product launch and pipeline shortly.”

Dr. Amit Kumar, President and CEO of CombiMatrix, and Chairman of CMDX stated, “Our goal for CMDX is to launch new array services in rapid succession. We hope to have, on the market, the broadest portfolio of array based molecular diagnostic products and services, of any microarray company, within the next two or three quarters. We have invested in and developed our technology platforms specifically to enable this rapid ‘turnkey’ type capability.”

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.

The CombiMatrix group is developing a platform technology to rapidly produce CUSTOMARRAYS™, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix's group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.

The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 47 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT®), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging, spreadsheet automation, user activated Internet advertising and web conferencing & collaboration software.

Acacia Research-Acacia Technologies (Nasdaq: ACTG) and Acacia Research-CombiMatrix (Nasdaq: CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.

Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.